Skip to main content
×
Home
    • Aa
    • Aa
  • Access
  • Cited by 1
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Fleiner, Tim Zijlstra, Wiebren Dauth, Hannah and Haussermann, Peter 2015. Evaluation of a hospital-based day-structuring exercise programme on exacerbated behavioural and psychological symptoms in dementia - the exercise carrousel: study protocol for a randomised controlled trial. Trials, Vol. 16, Issue. 1,


    ×

Antipsychotic drugs for psychosis and agitation in dementia: efficacy, safety, and a possible noradrenergic mechanism of action

  • Murray A. Raskind (a1) and Lucy Y. Wang (a1)
  • DOI: http://dx.doi.org/10.1017/S1041610214000477
  • Published online: 04 April 2014
Abstract

The first patient described by Alzheimer in 1907 had both progressive cognitive deterioration and prominent comorbid signs and symptoms of psychosis and agitation (Alzheimer, 1907, 1987). In this editorial, we use “psychosis” to denote delusions and hallucinations and “agitation” to denote irritability, aggression, pressured motor activity, and active resistance to necessary care. Although advances have been made in the treatment of these non-cognitive symptoms, these psychosis and agitation symptoms continued to be burdensome and costly for dementia patients, caregivers, and society. Among the pharmacologic treatments available for psychosis and agitation, antipsychotic drugs are the drug class most consistently demonstrated effective for psychosis and agitation in dementia (Lyketsos et al., 2006; APA Work Group on Alzheimer's Disease and Other Dementias et al., 2007). These are widely prescribed for these behavioral problems, but their use remains controversial and their mechanism of action unclear.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Antipsychotic drugs for psychosis and agitation in dementia: efficacy, safety, and a possible noradrenergic mechanism of action
      Your Kindle email address
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Antipsychotic drugs for psychosis and agitation in dementia: efficacy, safety, and a possible noradrenergic mechanism of action
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Antipsychotic drugs for psychosis and agitation in dementia: efficacy, safety, and a possible noradrenergic mechanism of action
      Available formats
      ×
Copyright
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

C. W. Berridge and B. D. Waterhouse (2003). The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Research Brain Research Review, 42, 3384.

W. Bondareff , C. Q. Mountjoy and M. Roth (1982). Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology, 32, 164168.

V. Chan-Palay and E. Asan (1989). Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer's type and in Parkinson's disease with and without dementia and depression. Journal of Comparative Neurology, 287, 373392.

P. P. De Deyn et al. (2004). Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 19, 115126.

P. De Deyn et al. (2005). Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. Journal of Clinical Psychopharmacoly, 25, 463467.

D. P. Devanand et al. (2012). Relapse risk after discontinuation of risperidone in Alzheimer's disease. New England Journal of Medicine, 367, 14971507.

S. I. Finkel et al. (1995). A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. International Journal of Geriatric Psychiatry, 10, 129136.

P. Kamble , H. Chen , J. T. Sherer and R. R. Aparasu (2009). Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs & Aging, 26, 483492.

I. Katz , P. P. de Deyn , J. Mintzer , A. Greenspan , Y. Zhu and H. Brodaty (2007). The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. International Journal of Geriatric Psychiatry, 22, 475484.

I. R. Katz , D. V. Jeste , J. E. Mintzer , C. Clyde , J. Napolitano and M. Brecher (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. Journal of Clinical Psychiatry, 60, 107115.

O. L. Lopez et al. (2013). The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. American Journal of Psychiatry, 170, 10511058.

C. G. Lyketsos et al. (2006). Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer's disease. American Journal of Geriatric Psychiatry, 14, 561572.

J. Mintzer et al. (2006). Risperidone in the treatment of psychosis of Alzheimer's disease: results from a prospective clinical trial. American Journal of Geriatric Psychiatry, 14, 280291.

J. E. Mintzer et al. (2007). Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer's dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. American Journal of Geriatric Psychiatry, 15, 918931.

H. A. Nasrallah (2008). Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular Psychiatry, 13, 2735.

E. J. Nestler , A. McMahon , E. L. Sabban , J. F. Tallman and R. S. Duman (1990). Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proceedings of the National Academy of Sciences USA, 87, 75227526.

A. L. Nyth and C. G. Gottfries (1990). The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. British Journal of Psychiatry, 157, 894901.

E. R. Peskind et al. (1995). Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Archives of General Psychiatry, 52, 774782.

E. R. Peskind et al. (2005). Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer's disease: a placebo-controlled study. Alzheimer Disease & Associated Disorders, 19, 2328.

B. G. Pollock et al. (2002). Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. American Journal of Psychiatry, 159, 460465.

A. P. Porsteinsson et al. (2014). Effect of citalopram on agitation in Alzheimer's disease: the cited randomized clinical trial. JAMA, 311, 682691.

M. M. Raivio , J. V. Laurila , T. E. Strandberg , R. S. Tilvis and K. H. Pitkala (2007). Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. American Journal of Geriatric Psychiatry, 15, 416424.

B. P. Ramos and A. F. Arnsten (2007). Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacology & Therapeutics, 113, 523536.

M. A. Raskind , E. R. Peskind , J. B. Halter and D. C. Jimerson (1984). Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arcives of General Psychiatry, 41, 343346.

M. A. Raskind et al. (2007). A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biological Psychiatry, 61, 928934.

M. A. Raskind et al. (2013). A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. American Journal of Psychiatry, 170, 10031010.

B. L. Roth , D. J. Sheffler and W. K. Kroeze (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews Drug Discovery, 3, 353359.

A. Russo-Neustadt , T. J. Zomorodian and C. W. Cotman (1998). Preserved cerebellar tyrosine hydroxylase-immunoreactive neuronal fibers in a behaviorally aggressive subgroup of Alzheimer's disease patients. Neuroscience, 87, 5561.

L. S. Schneider , K. S. Dagerman and P. Insel (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 294, 19341943.

L. Simoni-Wastila , P. T. Ryder , J. Qian , I. H. Zuckerman , T. Shaffer and L. Zhao (2009). Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities. American Journal of Geriatric Psychiatry, 17, 417427.

J. S. Street et al. (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Archives of General Psychiatry, 57, 968976.

J. E. Streim et al. (2008). A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer's disease. American Journal of Geriatric Psychiatry, 16, 537550.

P. Szot , S. S. White , J. L. Greenup , J. B. Leverenz , E. R. Peskind and M. A. Raskind (2006). Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. Journal of Neuroscience, 26, 467478.

P. Szot , S. S. White , J. L. Greenup , J. B. Leverenz , E. R. Peskind and M. A. Raskind (2007). Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience, 146, 471480.

P. N. Tariot et al. (2006). Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. American Journal of Geriatric Psychiatry, 14, 767776.

B. E. Tomlinson , D. Irving and G. Blessed (1981). Cell loss in the locus coeruleus in senile dementia of Alzheimer type. Journal of the Neurological Sciences, 49, 419428.

L. Y. Wang et al. (2009). Prazosin for the treatment of behavioral symptoms in patients with Alzheimer's disease with agitation and aggression. American Journal of Geriatric Psychiatry, 17, 744751.

C. H. West , J. C. Ritchie , K. A. Boss-Williams and J. M. Weiss (2009). Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. International Journal of Neuropsychopharmacology, 12, 627641.

K. X. Zhong , P. N. Tariot , J. Mintzer , M. C. Minkwitz and N. A. Devine (2007). Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Current Alzheimer Research, 4, 8193.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×